Sol-Gel Technologies to host KOL event for Gorlin syndrome drug SGT-610
Sol-Gel Technologies will host a Key Opinion Leader (KOL) investor event on SGT-610 (patidegib gel, 2%) on Oct. 14, 2026, in New York. The event will focus on the disease burden of Gorlin syndrome and the lack of effective therapies.